Positive results from human PK study assessing Orexo’s intranasal nalmefene formulations for opioid overdose reversal
· Preliminary data indicate extensive and rapid absorption of OX125 across all formulations · Positive results underline the applicability of Orexo’s novel intranasal drug delivery platform Uppsala, Sweden - June 30, 2020 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive results from its human pharmacokinetic (PK) study of OX125. The study was a cross-over, comparative bioavailability study in healthy volunteers to assess nalmefene absorption from three development formulations of OX125, Orexo's wholly-owned nasal nalmefene product, compared to a nalmefene